Forxiga approved in Japan for the treatment of chronic kidney disease in patients with and without type-2 diabetes
Approval marks an important transformation in the treatment of more than 13 million people suffering from chronic kidney disease in JapanAstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in Japan for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). The approval by Japan’s Ministry of Health, Labour and Welfare (MHLW) is based on positive results from the DAPA-CKD Phase III trial.[1 ]The decision follows the Priority Review designation granted by the MHLW earlier this year. CKD is